Biotechnology News and Information. Includes Arizona Biotechnology, Arizona Biotech news, genomics, biotech companies, genetic engineering, biotech research, biology and biological technology news and information.

BioTech News at Arizona Biotech

Biotech News <<< Mailing List

Biotechnology News <<< Discussion Forums

This site is a member of WebRing.
To browse visit Here.

Friday, January 20, 2006

[ biotech news ] 11th Institute of Biological Engineering Meeting

11th Institute of Biological Engineering Meeting

http://www.ibeweb.org/meetings/2006/index.cgi

The 2006 Annual Meeting of the Institute of Biological Engineering
(IBE) will be held from March 10 through 12, 2006 at the Hilton
Tucson East in Tucson, Arizona, USA.

The theme of the meeting is "Biology-Inspired Engineering", with Jay
D. Keasling as the Keynote Speaker on Friday, March 10. Friday
afternoon during the Bio-Business Nexus session, new innovated bio-
based products will be showcased.

Winners of the first IBE conducted Bioethics Essay Contest for
undergraduate and graduate students will be announced at the general
session on Saturday, March 11.

The 11th Annual Meeting will be a distinctive occasion for attendees
to collaborate in education, research and economic activities.

Early registration is offered through January 31, 2006.

http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] After 5 Showcase - Ribomed Biotechnologies

After 5 Showcase - Ribomed Biotechnologies
1/25/06

http://tinyurl.com/dh9u6

Date: Wednesday, January 25, 2006
Time: 5:00pm - 7:00pm
Location: Ribomed (714 East Van Buren Street, Suite 101, Phoenix
85006)
No cost to attend
Register: Jennifer Coombs jcoombs@phoenixchamber.com

The Arizona Technology Council and the Greater Phoenix Chamber of
Commerce are pleased to present Ribomed Biotechnologies, Inc. as the
January After 5 Showcase company. Please join us for an inside peek
at Ribomed Biotechnologies and their new facility.

Dr. Hanna Info:
Dr. Michelle Hanna, President & CEO has more than 20 years of
experience in chemistry and molecular biology. She left her tenured
faculty position 6 years ago and started Ribomed Biotechnologies,
Inc. (formerly known as Designer Genes, Inc.) to commercialize
technologies she developed while a university professor. Over the
past 21 years Dr. Hanna's been awarded and effectively managed more
than $7 million in grants from the ACS, NCI, NIH, NIAID, DARPA and
HSARPA.

Ribomed Info:
Ribomed Biotechnologies, Inc. is a molecular diagnostics company
developing rapid, specific, and robust tests for the early detection
and characterization of diseases and their causative agents, and the
screening of drugs for treatment. Ribomed Biotechnologies, Inc. is
dedicated to improving the quality of life through early disease
detection, noninvasive monitoring, and patient-specific therapies.

The RiboMaker® Detection System is being adapted for a number of
applications in both clinical diagnostics and biodefense. In the
clinical arena, Ribomed plans to target its technology for use in
blood bank screening for RNA viruses and cancer diagnostics.
Ribomed is pursuing a number of opportunities in the biodefense
sector and is currently partnered with Northrup Grumman, a leading
biodefense contractor, on the development of a handheld sensor for
the detection of bioterror pathogens.

Ribomed's innovative technology has been recognized by the leading
market research firm, Frost & Sullivan, with its award to Ribomed of
the Biological Detection Technologies Excellence in Research of the
Year Award for 2005.

Tour Info:
Dr. Michelle Hanna will be giving a brief talk about Ribomed
Biotechnologies, Inc. history and technology, followed by a tour of
Ribomed Biotechnologies, Inc. laboratories, offices and the Phoenix
Biotechnology Accelerator (P-Bio) facilities. The Phoenix
Biotechnology Accelerator, LLC was formed by Dr. Michelle Hanna and
her mother, Mrs. Arlene Knight-Kilgore. The mission of P-Bio is to
develop a BioIndustry Park adjacent to the Phoenix Biosciences
Center in downtown Phoenix, which includes the Translational
Genomics Institute and the International Genomics Consortium. P-Bio
provides affordable, flexible leases for start-up biotechnology
companies.

Location / Parking Info:
Ribomed Biotechnologies, Inc. is located on the Northeast corner of
7th Street and Van Buren Street, next to the Marriott Springhill
Suites. It is a single story building with the entrance to the
parking lot off Van Buren Street. There is plenty of parking
located in the East lot as well as in the adjacent North lot.

http://www.aztechcouncil.org/eventsopen.cfm?
id=358&nav=events&month=1

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, January 18, 2006

Biodiesel

The Answer is Biodiesel

Biotech News

ChangeThis :: The Answer is Biodiesel

Michael Briggs Trade in your Prius and buy a VW! What's better than hybrids and better than fuel cells? According to UNH researcher Michael Briggs, the answer is Biodiesel. Read his manifesto to find out why biodiesel is cheaper and more environmentally-friendly to produce, ready for large-scale production, and usable in existing automobiles. The results may surprise you.

Change This :: The Answer is Biodiesel
About the author:
The UNH Biodiesel Group is working on improving the technology for growing algae on waste streams for biodiesel production. UNH has ﬁled a provisional patent application and is seeking partners to develop the technology.

ChangeThis

The Answer is Biodiesel PDF File

Why Craigslist Works

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Saturday, January 14, 2006

[ biotech news ] Genentech Submits Biologics License Application for FDA Review of Lucentis(TM)

Genentech Submits Biologics License Application for FDA Review of
Lucentis(TM) in Wet Age-Related Macular Degeneration

BLA Includes Request for Priority Six-Month Review

SOUTH SAN FRANCISCO, Calif., Dec. 30 /PRNewswire-FirstCall/ --
Genentech,
Inc. (NYSE: DNA) announced today that it has submitted a Biologics
License
Application (BLA) to the U.S. Food and Drug Administration (FDA) for
the use
of Lucentis(TM) (ranibizumab) in the treatment of neovascular wet
age-related
macular degeneration (AMD). Lucentis is the first therapy for wet
AMD to have
shown improved vision in two pivotal Phase III trials and
demonstrated a
clinical benefit over verteporfin (Visudyne(R)) photodynamic therapy
(PDT) in
a head-to-head clinical trial. As part of the Lucentis BLA
submission,
Genentech has requested a Priority Review designation from the FDA,
which, if
granted, would give the FDA six months from the Agency's receipt of
the
submission to take action on the application.
The BLA submission is based on one-year clinical data on the
efficacy and
safety of Lucentis from two pivotal Phase III trials, ANCHOR and
MARINA, as
well as one-year clinical data from the Phase I/II FOCUS trial. In
addition
to these registrational studies, Genentech is currently enrolling
patients
with wet AMD in a Phase IIIb safety study called SAILOR. Data from
the Phase
IIIb PIER study evaluating a less frequent dosing regimen for
Lucentis are
anticipated in the first half of 2006.
"This application represents a summary of data from more than
six years of
rigorous clinical study and the dedication of thousands of patients
and
physicians hoping to improve outcomes for those with this devastating
disease," said Hal Barron, M.D., Genentech's senior vice president of
Development and chief medical officer. "We look forward to working
with the
FDA in our efforts to bring this potential therapy to patients
quickly as it
may offer benefit to patients with all types of wet AMD."

ANCHOR
In November 2005, Genentech announced positive preliminary data
from the
pivotal Phase III ANCHOR study (ANti-VEGF Antibody for the Treatment
of
Predominantly Classic CHORoidal Neovascularization in AMD), a
randomized,
two-year, multi-center, double-masked, active-treatment controlled
study
comparing two different doses of Lucentis to PDT in 423 patients with
predominantly classic wet AMD. Approximately 94 percent of patients
treated
with 0.3 mg of Lucentis and 96 percent of those treated with 0.5 mg
of
Lucentis maintained (defined as a loss of less than 15 letters in
visual
acuity) or improved vision (defined as a gain of 15 letters or more)
compared
to approximately 64 percent of those treated with PDT alone
[p<0.0001] during
the first year of the two-year study. The Lucentis treatment groups
further
showed a statistically significant difference from the control arm
in an
important secondary endpoint: mean change in visual acuity (VA) from
baseline
to month 12. On average, VA among patients treated with Lucentis
improved,
while VA among patients treated with PDT declined. Based on these
results,
patients in the PDT-alone arm of the study will have access to
Lucentis for
the remainder of the study. One-year data from the ANCHOR study
will be
presented at the Macula 2006 meeting in New York in January.

MARINA
In July 2005, Genentech presented positive preliminary one-year
results
from the pivotal Phase III MARINA study (Minimally classic/occult
trial of the
Anti-VEGF antibody Ranibizumab In the treatment of Neovascular AMD),
a
randomized, two-year, multi-center, double-masked, sham-injection
controlled
study evaluating the safety and efficacy of two different doses of
Lucentis in
716 patients with minimally classic or occult wet AMD. Nearly 95
percent of
patients treated with Lucentis maintained or improved vision at 12
months.
Additional one-year results include:

-- Twenty five percent (59/238) of patients treated with 0.3
mg of
Lucentis and 34 percent (81/240) treated with 0.5 mg of
Lucentis
improved vision by a gain of 15 letters or more compared to
approximately 5 percent (11/238) of patients in the control
group as
measured by the ETDRS eye chart.
-- Nearly 40 percent (188/478) of Lucentis-treated patients
(38.7 percent in the 0.3 mg group and 40 percent in the 0.5
mg group)
achieved a visual acuity score of 20/40 or better compared
to
11 percent (26/238) in the control group.
-- Patients treated with Lucentis gained an average of
approximately
seven letters in visual acuity (6.5 letters in the 0.3 mg
group and
7.2 letters in the 0.5 mg group) compared to study entry,
while those
in the control group lost an average of 10.5 letters.
-- The majority of patients treated with Lucentis (349/478)
(74.8 percent in the 0.3 mg group and 71.3 percent in the
0.5 mg
group) experienced a letter improvement of zero or more
compared to
28.6 percent (68/238) in the sham group.

In October 2005, Genentech announced that patients still in the
sham arm
of the MARINA study would be crossed over to active treatment with
Lucentis.

FOCUS
The FOCUS trial (RhuFab V2 Ocular Treatment Combining the Use of
Visudyne(R) to Evaluate Safety) is a randomized, two-year, multi-
center,
single-masked study evaluating the safety, tolerability and efficacy
of
Lucentis in combination with PDT compared to PDT alone in 162
patients with
predominantly classic subfoveal wet AMD. Preliminary one-year data
were
presented in July 2005 and showed that approximately 90 percent of
patients
maintained or improved vision when treated with the combination of
Lucentis
and PDT compared to approximately 68 percent of those treated with
PDT alone
(p = 0.0003).

Lucentis Safety Profile
In clinical trials to date, the most common side effects that
occurred
more frequently in the Lucentis arms (0.3 mg and 0.5 mg) than in the
control
arms were mild to moderate and included: conjunctival hemorrhage,
eye pain,
increased intraocular pressure and vitreous floaters.
Serious ocular adverse events that occurred more frequently in
the
Lucentis-treated arms were uncommon and included endophthalmitis and
intraocular inflammation (less than 1 percent for each). Among non-
ocular
serious adverse events, cerebral vascular events and myocardial
infarctions
were observed in all three arms of both the Phase III MARINA and
ANCHOR
studies; in each study the combined rate of these events was similar
in the
control and the 0.3 mg Lucentis arms and slightly higher in the 0.5
mg
Lucentis arm. Cerebral vascular events and myocardial infarctions
were also
seen in the Phase I/II study of Lucentis 0.5 mg in combination with
Visudyne
PDT (FOCUS), although the combined frequency of these events was
approximately
equal in both treatment arms.

Additional Phase III Studies

SAILOR
In November 2005, Genentech began enrollment in a Phase IIIb
study,
SAILOR, to make Lucentis available to eligible patients. SAILOR
(Safety
Assessment of Intravitreal Lucentis fOR AMD) is a Phase IIIb
clinical study of
Lucentis for patients with all types of new or recurrent active
subfoveal wet
AMD. It is a one-year study designed to evaluate the safety of two
different
doses (0.3 mg and 0.5 mg) of Lucentis administered once a month for
three
months and thereafter as needed based on retreatment criteria. The
study will
be conducted at more than 100 sites in the United States and will
enroll up to
5,000 patients. Those interested in additional information about the
study can
call toll-free 1-888-662-6728.

PIER
Genentech is also conducting PIER (A Phase IIIb, Multi-center,
Randomized,
Double-Masked, Sham Injection-Controlled Study of the Efficacy and
Safety of
Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization
with or
without Classic CNV Secondary to Age-Related Macular Degeneration)
with
184 patients in the United States. In this trial, Lucentis is
administered
once per month for the first three months followed thereafter by
doses once
every three months for a total of 24 months. Enrollment in this
study is
complete and preliminary results are expected in the first half of
2006.

About AMD
AMD is a major cause of painless central visual loss and is the
leading
cause of blindness for people over the age of 60. The National Eye
Institute
estimates that there are 1.6 million people with AMD in the United
States
alone and that this prevalence will grow to 2.95 million by 2020.
AMD occurs
in two forms: dry and wet.
The dry form is associated with atrophic cell death of the
central retina
or macula, which is required for fine vision used for activities
such as
reading, driving or recognizing faces. The wet form is caused by
growth of
abnormal blood vessels also known as choroidal neovascularization
(CNV) or
ocular angiogenesis under the macula. These vessels leak fluid and
blood and
cause scar tissue that destroys the central retina. This results in
a
deterioration of sight over a period of months to years.

About Lucentis
Lucentis(TM) (ranibizumab) is a humanized therapeutic antibody
fragment
developed at Genentech and designed to bind and inhibit VEGF-A, a
protein that
is believed to play a critical role in angiogenesis (the formation
of new
blood vessels). Lucentis is designed to block new blood vessel
growth and
leakiness, which lead to wet AMD disease progression and vision loss.
Lucentis is being developed by Genentech and the Novartis
Ophthalmics
Business Unit. Genentech retains commercial rights for Lucentis in
North
America. Novartis has exclusive commercialization rights for the
rest of the
world.

About Angiogenesis
Genentech is a leader in research and product development in the
area of
angiogenesis, the process by which new blood vessels are formed. In
1989
Napoleone Ferrara, M.D., and a team of scientists at Genentech
conducted
seminal work in the field, which resulted in the identification and
cloning of
a gene termed Vascular Endothelial Growth Factor (VEGF), now known
as VEGF-A.
The VEGF-A protein is believed to play a critical role in
angiogenesis and
serves as one of the key contributors to physiological or
pathological
conditions that can stimulate the formation of new blood vessels.
The process
of angiogenesis is normally regulated throughout development and
adult life,
and the uncontrolled growth of new blood vessels is an important
contributor
to a number of pathologic conditions, including wet AMD.

About Genentech
Genentech is a leading biotechnology company that discovers,
develops,
manufactures and commercializes biotherapeutics for significant
unmet medical
needs. A considerable number of the currently approved
biotechnology products
originated from, or are based on, Genentech science. Genentech
manufactures
and commercializes multiple biotechnology products directly in the
United
States and licenses several additional products to other companies.
The
company has headquarters in South San Francisco, Calif., and is
traded on the
New York Stock Exchange under the symbol DNA. For additional
information
about the company, please visit http://www.gene.com .

This press release contains forward-looking statements regarding
Lucentis
as a potential therapy and the expected time frame for the PIER
trial results.
Actual results could differ materially. Among other things, the
time frame
for the PIER results could be affected by unexpected safety or
efficacy
issues, additional time requirements to achieve study endpoints or
for data
analysis, or discussions with the FDA or FDA actions; and Lucentis
as a
potential therapy could be affected by certain of the forgoing and
the failure
to receive FDA approval, competition, pricing and the ability to
supply
product or a product withdrawal. Genentech disclaims any obligation
and does
not undertake to update or revise the forward-looking statements in
this press
release.

Media Contact: Dawn Kalmar 650-225-5873
Investor Contact: Kathee Littrell 650-225-1034
Patient Inquiries: 1-888-662-6728

SOURCE Genentech, Inc.
Web Site: http://www.gene.com

http://groups.yahoo.com/group/biotech-news/
http://www.quotes-world.com/
http://www.perceptionofdifference.com/
http://groups.yahoo.com/group/funny-jokes/
http://www.arizonabiotech.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Thursday, January 12, 2006

[ biotech news ] Quintek to Deliver Services Nationally to Major Biotechnology Company With Annua

Quintek to Deliver Services Nationally to Major Biotechnology
Company With Annual Sales of $12 Billion

http://groups.yahoo.com/group/biotech-news/

Quintek Technologies, Inc. (OTC BB: QTEK), a global provider of
Business Process Outsourcing (BPO) and best-of-breed technology
consulting services, today announced that it has received a signed
agreement to deliver services nationally to a major biotechnology
company.

This agreement represents additional business resulting from
Quintek's previously disclosed relationship with a $29 billion
international transportation, e-commerce and business solutions
provider. The end user of the services is a biotechnology company
generating roughly $12 billion a year in revenues, engaged in the
discovery, development, manufacture, and marketing of human
therapeutics based on advances in cellular and molecular biology.
Quintek received the additional business after providing services to
this company for over six months.

Effective immediately, Quintek will expand from 1 to 4 sites,
providing services throughout the US for this customer. Quintek
estimates that billings should increase significantly from this
newly executed agreement. "The additional business should increase
revenues from this account by over 100%. The annual estimated run
rate of $216,000 should grow to roughly $504,000," commented Andrew
Haag, CFO of Quintek. "This additional business, from an existing
customer, is a strong vote of confidence."

Robert Steele, CEO of Quintek stated, "This is a solid agreement,
with fixed monthly minimum billings." He added, "We are currently
delivering services for several multi-billion dollar customers that
are leaders in their industry; we plan to grow the business around
this model."

About Quintek Technologies, Inc.

Quintek Technologies, Inc. (OTC BB: QTEK), through its wholly owned
subsidiaries Quintek Services, Inc. (QSI), and Sapphire Consulting
Services, Inc., provides services to enable Fortune 500 and Global
2000 corporations to reduce costs and maximize revenues.

QSI delivers Business Process Outsourcing (BPO) services and
solutions that enable companies to secure and manage their key data
processing demands with optimal efficiency and minimal costs. As a
next-generation technology company, Quintek is unhindered by
outdated information technology systems, and thus is able to deploy
best-of-breed solutions in all aspects of BPO. The Aberdeen Group, a
provider of IT market intelligence, forecasts 13% annual growth for
the BPO industry through 2005, when the market is projected to reach
$248 billion.

Sapphire Consulting Services, Inc. offers a broad range of supply
chain management consulting services. Sapphire assists organizations
to create a higher level of customer satisfaction, enhance supply
chain capability and achieve consistent competitive advantage
through reduced product cost, reduced inventory investment and
improved supply chain security. A study by IDC found the SCM
services market will expand from $26.1 billion in 2002 to $40.5
billion in 2007, representing a five-year compound annual growth
rate (CAGR) of 9.2%.

For more information, visit http://www.quintek.com.

This press release contains forward-looking information within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), including statements regarding
potential sales, the success of the company's business, as well as
statements that include the word "believe" or similar expressions.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of Quintek to differ materially from
those implied or expressed by such forward-looking statements. Such
factors include, among others, the risk factors included in
Quintek's Annual Report on Form 10-KSB for the fiscal year ended
June 30, 2005 and any subsequent reports filed with the SEC under
the Exchange Act. This press release speaks as of the date first set
forth above and Quintek assumes no responsibility to update the
information included herein for events occurring after the date
hereof. Actual results could differ materially from those
anticipated due to factors such as the lack of capital, inability to
timely develop of products or services, inability to deliver
products or services when ordered, inability of potential customers
to pay for ordered products or services, and political and economic
risks inherent in domestic and international trade.

http://www.quotesquotes.com/
http://www.perceptionofdifference.com/
http://groups.yahoo.com/group/famous-quotes-/
http://www.arizonabiotech.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] BioTech Medics, Inc. Answers Lawsuit and Files Counterclaim

BioTech Medics, Inc. Answers Lawsuit and Files Counterclaim

BioTech Medics, Inc. (OTC Pink Sheets: BTMD) announced that the
company, as Defendant, had been served with a Texas civil defamation
action by Adam Barnett, a Florida resident, as Plaintiff. BioTech
has vigorously denied Barnett's allegations and filed a counterclaim
against him, and has also filed a third-party petition against
William Seminario, a Florida resident, and Hamilton Holdings PA
Corp., a Pennsylvania corporation.

BioTech's counterclaim and third party petition alleges that
Barnett, Seminario and Hamilton conspired to unlawfully deprive
BioTech of over 12 Million shares of its common stock and
manipulated the value of BioTech's common stock. BioTech further
alleges in its counterclaim against Barnett that Barnett, using a
series of aliases, published false and defamatory statements against
BioTech and its management, using the Internet.

Keith Houser, CEO of BioTech, stated "We will aggressively pursue
this litigation until its conclusion. We have also been in contact
with the Securities and Exchange Commission-Enforcement Division
about our allegations and intend to continue to assist the SEC in
their investigation in any way we can."

Source: BioTech Medics, Inc.
Contact: Keith Houser, CEO
972-849-2772

Safe Harbor for Forward-Looking Statements.
This press release may contain forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995
(the "Act"). In Particular, when used in the preceding discussion,
the words "plan," "confident
that," "believe," "scheduled," "expect," or "intend to," and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the safe
harbor created by the Act. Such statements are subject to certain
risks and uncertainties and actual results could differ materially
from those expressed in any of the forward-looking statements.

http://groups.yahoo.com/group/biotech-news/
http://www.quotesquotes.com/
http://www.perceptionofdifference.com/
http://groups.yahoo.com/group/famous-quotes-/
http://www.arizonabiotech.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Hawaii Conference Highlights Another Consumer Benefit of Biotechnology

Hawaii Conference Highlights Another Consumer Benefit of
Biotechnology

WASHINGTON, Jan. 9 The Biotechnology Industry Organization
(BIO) is hosting the Pacific Rim Summit on Industrial Biotechnology
and Bioenergy Jan. 11-13, 2006 at the Hilton Hawaiian Village Beach
Resort and Spa in Honolulu to explore the third wave in
biotechnology -- industrial and environmental biotechnology, which
is the use of life science technologies to improve manufacturing
processes. "Biotechnology is creating a new industrial revolution
based on biology instead of petroleum. As biotech processes replace
old rust belt technologies, they are enabling a transformation from
a petroleum-based economy to a biobased economy," states Brent
Erickson, executive vice president of BIO's Industrial and
Environmental Section.

Industrial enzymes are already being used to make a number of
consumer
products better. Most detergents contain enzymes that help remove
food and
grass stains and get our clothes cleaner, even when cold wash water
is used.
Contact lens cleaners utilize biotech enzymes to remove tough
protein deposits
from lenses. Enzymes can be used to bleach paper products replacing
the use of
toxic chlorine. There are enzymes used to keep bread from going
stale and to
make the high-fructose sweeteners in our juice and soft drinks.
Biotech can also be used to make ethanol for our cars and
plastics for
consumer products out of agriculture waste products instead of crude
oil. The
United States currently makes about 4 billion gallons of ethanol a
year from
grain, primarily corn. New biotechnology processes are now available
that
could produce over 70 billion gallons of ethanol a year from
cellulose-
containing crop residues, such as corn stover and stalks, sugar cane
bagasse,
wheat straw and rice straw. Biotech-improved enzymes convert the
cellulose to
sugars that can be fermented into ethanol.
Biotech enzymes are also being used to transform the chemical
industry.
Enzyme biocatalysts are used as substitutes for chemicals in many
manufacturing processes, reducing process costs, the amount of
energy used to
make products, and the amount of greenhouse gases emitted. "When
companies
change a process from a chemical synthesis process to a
biotechnology process
and use enzymes, they actually prevent pollution from being
generated because
toxic chemicals are no longer required to make a product," said
Erickson.
All living systems, including microorganisms, produce enzymes
that act as
biocatalysts to perform a myriad of chemical functions in living
cells.
Industrial biotechnology involves working with nature to optimize
existing
biochemical systems -- that can replace traditional chemical
processes in
manufacturing. Scientists use biotech techniques to research
microorganisms --
ranging from bacteria, yeasts, and fungi to marine diatoms and
protozoa -- to
identify and produce enzymes for manufacturing, environmental
cleanup, and
other industrial applications.
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the
United States and 31 other nations. BIO members are involved in the
research
and development of healthcare, agricultural, industrial and
environmental
biotechnology products.

SOURCE Biotechnology Industry Organization
Web Site: http://www.bio.org

http://groups.yahoo.com/group/biotech-news/
http://www.quotes-world.com/
http://www.perceptionofdifference.com/
http://groups.yahoo.com/group/funny-jokes/
http://www.arizonabiotech.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Industrial Biotechnology Journal Celebrates Inaugural Year

Industrial Biotechnology Journal Celebrates Inaugural Year by
Providing Free Online Access

http://www.arizonabiotech.com/

NEW ROCHELLE, N.Y. Jan 10, 2006 - Industrial Biotechnology, the
premier publication in and voice of this important, emerging field,
is celebrating its inaugural year by releasing the entire first
year's volume for complimentary online access through March 15,
2006, at www.indbiotech.com/issues. An authoritative,
multidisciplinary news and peer-reviewed research publication, the
Journal is published by GEN Publishing Inc., a Mary Ann Liebert,
Inc., company (www.liebertpub.com).

Industrial biotechnology applies classical and new biotechnology
methods to improve environmental sustainability, reduce costs, and
increase efficiency of manufacturing processes in every sector, and
is predicted to have a sweeping impact on global industries as
diverse as bioenergy to pulp and paper to textiles to foods.

Industrial Biotechnology is a media sponsor of the BIO Pacific Rim
Summit on Industrial Biotechnology and Bioenergy, which begins
tomorrow in Honolulu, Hawaii (January 11-13). One focus will be the
critical field of alternative energy sources, which Industrial
Biotechnology seeks to advance.

"Recent developments in enzyme discovery and improvement are a
harbinger for worldwide adoption of new, more productive biofuel
technologies that use agriculture crop wastes as feedstocks. These
have the potential to end international competition for finite
fossil fuel supplies, as nations develop novel, locally available
sources of energy," says Brent Erickson, Executive VP of the
Industrial and Environmental Section of BIO, and Industrial
Biotechnology's Consulting Editor.

"Industrial Biotechnology is an important, forerunner publication in
the field, presenting scientific developments that foster the
dialogue needed among policymakers, financiers, and researchers to
advance these important technologies through to commercialization."

In addition to reducing global climate-change emissions, industrial
biotechnology is also permitting novel means of manufacturing
existing consumer products and of developing altogether new "green"
consumer products, advancing sustainable economic development,
Erickson adds.

Industrial Biotechnology presents technical papers, original
research, and expert commentary articles in genomics, proteomics,
metabolomics, biological, chemical engineering, and environmental
engineering, and bioprocess. Applications range from bioenergy, pulp
and paper, textiles, to bioremediation, bioplastics, mining, and
automotive.

Mary Ann Liebert, Inc., publishers, is a privately held, fully
integrated media company known for authoritative peer-reviewed
journals in science and biomedicine, including Environmental
Engineering Science, Biotechnology Law Report, and Biosecurity and
Bioterrorism. The company's biotechnology trade magazine, Genetic
Engineering News (GEN), was the first in its field and is today the
industry's most widely read trade publication worldwide. A complete
list of the company's 60 journals, news magazines, and books is
available at www.liebertpub.com.

http://groups.yahoo.com/group/biotech-news/
http://www.quotes-world.com/
http://www.perceptionofdifference.com/
http://groups.yahoo.com/group/funny-jokes/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Wednesday, January 04, 2006

[ biotech news ] 2005: A Year of Success for Plant and Animal Biotechnology

2005: A Year of Success for Plant and Animal Biotechnology

"Significant achievements were made in the adoption and acceptance
of agricultural biotechnology for improved crops and animals in
2005," said Sean Darragh, executive vice president of the
Biotechnology Industry Organization (BIO).

"A major milestone was reached in May when the one billionth
acre of biotech crops was sown capping a decade of plantings in 18
countries around the globe," added Darragh. He also pointed out
that more than 90 percent of the 8 million farmers growing biotech
crops were located in developing nations.

"While the first generation of plant biotech products directly
benefited farmers and the environment, the next generation of plant
biotech research is focused on providing consumer benefits,
including the development of biotech plants that offer increased
nutrition and health benefits," said Darragh.

In addition to record acceptance by farmers, scientists
continued to increase their understanding and knowledge of plants
and animals through genome sequencing projects. In 2005, the rice
and dog genomes were mapped, and projects to sequence soybean, corn,
and sheep genomes were announced.

Researchers use these genetic maps to improve the nutrient quality
of food
crops and strengthen plants' abilities to resist drought conditions,
insect
infestation and plant disease. In addition, by understanding the
makeup of
animals at a cellular level, scientists can develop leaner and more
nutritious
dairy and meat products, as well as help animals to live healthier
lives.
An example of the importance of developing nutrient-enhanced
biotech
plants, especially for developing countries, were $36.8 million in
grants to
research projects focused on improving nutrition and health through
biotech-
improved bananas, cassava, rice, and sorghum by the Bill and Melinda
Gates
Foundation.
2005 also saw other important biotech developments with consumer
benefits
including:

* Kellogg announced it will use low-linolenic soybean oil to
reduce or
eliminate trans fats in several of its products; though the
soybeans
were produced through conventional breeding techniques, they
do contain
biotech traits and are the first products in the next
generation of
biotech products with consumer benefits.

* Australian researchers developed a biotech improved cress that
contains
healthy omega-3 oils in their seeds. Omega-3 oils are known
to help
reduce the risk of heart disease.

* Research into edible vaccines continued with the development
of a
biotech potato that carries the Hepatitis B vaccine, and a
biotech
tomato containing a SARS vaccine. Initial tests in human
subjects have
shown that the biotech potato confers immunity against
Hepatitis B.
Japanese scientists also announced the development of an
edible vaccine
in biotech rice that prevents the immune response that triggers
allergies related to hay fever.

* Japanese researchers developed a biotech soybean that contains
a
substance that promotes hair growth and helps prevent hair
loss caused
by chemotherapy. An antihypertensive substance derived from
egg whites
was incorporated into the soybean; the substance expands blood
vessels
and promotes circulation and hair growth.

There were also advances in animal biotechnology research which
will lead
to improved animal health, more nutritious and safer food products
from
animals, advances in human health, and conservation of both the
environment
and endangered animals. They include:

* USDA biotech researchers announced a breakthrough that will
help cows be
naturally resistant to mastitis, a bacterial infection of
cows' milk
glands that causes inflammation and swelling and a loss in milk
production. The biotech cows produce the protein lysostaphin,
which
significantly decreases the likelihood of developing mastitis,
which
causes up to a $2 billion loss annually for dairy farmers in
the United
States.

* Chickens, cows and pigs were improved through biotechnology as
part of
research to improve human health. In June, Scottish scientists
developed a method of producing antibodies that treat
malignant skin
cancer in chicken egg whites improved through biotechnology.
The new
production technique could allow for the development of a wide
range of
cancer treatments in greater volume and in a more cost-
efficient method
than conventional manufacturing techniques.

* In Argentina, cows were improved with biotechnology to produce
human
growth hormones in their milk. Scientists estimate that just
15 of
these Jersey cows could produce enough human growth hormone to
meet the
current world demand for the hormone.

* Work continued in South Korea on xenotransplantation, with
piglets
improved through biotechnology that contain an "HLA-G" gene,
which give
their organs an increased change of acceptance if transplanted
into
humans. Immuno-rejection is one of the major hurdles to
xenotransplantation; the introduced gene in the cloned piglets
may
reduce the chance of organ rejection.

* In animal conservation, an endangered species of Mongolian
gazelle was
cloned for the first time. 2005 also marked several other
animal
cloning firsts, including water buffalo and an Arab endurance
champion
horse. In addition, the United Kingdom announced approval to
clone
horses for research using somatic nuclear transfer techniques.

And finally, throughout the year, many international
organizations
continued to add to the collection of scientific literature that
highlights
the benefits of agricultural biotechnology:

* The World Health Organization (WHO) reported that biotech
foods can
"contribute to enhancing human health and development." The
study found
that biotech foods can increase crop yield, food quality, and
the
diversity of foods which can be grown in a given area, and
lead to
better health and nutrition, and thereby raise health and
living
standards.

* A report issued by USDA's Economic Research Service (ERS) and
Rutgers
University also found that large farms and small-scale farmers
in
southern Africa can benefit from planting biotech corn. The
report
found that yields on large farmers increased about 11 percent,
and
yields for small farms increased anywhere from seven to 56
percent, when
biotech corn was planted.

* A National Center for Food and Agriculture Policy (NCFAP)
study found
that the 118 million acres of biotech crops U.S. farmers
planted in 2004
increased food production by 6.6 billion pounds, and provided
$2.3
billion in additional net returns for U.S. growers. Biotech
crops also
reduced pesticide use by an additional 34 percent, or 15.6
million
pounds.

* The British research firm PG Economics Ltd. found that the
global use of
biotechnology-derived crops has added $27 billion to farm
income and
greatly reduced agriculture's negative impacts upon the
environment.

* An April, Science published a study by researchers at Rutgers
University
and the University of California, Davis who found that biotech
rice in
China could decrease farmer's production costs, increase
harvest yields,
reduce the use of pesticides by as much as 80 percent, and
improve
farmer health. The study also estimated that if "90 percent
of the
farmers plant [biotech] rice, the annual agricultural income
of China
will increase by $4 billion."

* A study by the University of Connecticut and Japan's Kagoshima
Prefectural Cattle Breeding Development Institute found that
meat and
milk products from cloned cattle are safe for consumption.
The results
reiterate those found by the National Academy of Science in
2001.

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the
United States and 31 other nations. BIO members are involved in the
research
and development of healthcare, agricultural, industrial and
environmental
biotechnology products.

SOURCE Biotechnology Industry Organization
Web Site: http://www.bio.org

http://www.arizonabiotech.com/
http://www.quotescentral.com/index.php
http://groups.yahoo.com/group/biotech-news/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

[ biotech news ] Wyeth Announces Strategic Collaboration with Trubion Pharmaceuticals

Wyeth Announces Strategic Collaboration with Trubion Pharmaceuticals

Development & Commercialization of Innovative
SMIP Biopharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Trubion
Pharmaceuticals, Inc. announced today that they have formed a
strategic alliance for the discovery, development and
commercialization of novel biopharmaceutical
products to treat inflammatory disease and cancer. The alliance
will utilize Trubion's proprietary Small Modular
Immunopharmaceutical (SMIP(TM)) technology.
SMIPs represent a novel class of immunotherapeutics with
enhanced drug properties over monoclonal and recombinant
antibodies. SMIPs are smaller than
antibodies and can reach sites unavailable to larger molecules while
exhibiting selective binding and long in vivo half-lives, which
means the
medicine is metabolized more slowly by the body suggesting less
frequent
dosing will be needed. These novel compounds can be expressed in
mammalian
cells and customized for many disease targets.
As part of the alliance, Wyeth and Trubion will collaborate on
the
development and commercialization of CD20-targeted therapies
including
TRU-015, a novel SMIP compound currently in phase 2 clinical
development for
the treatment of rheumatoid arthritis (RA). TRU-015 is designed to
deplete B
cells -- a new therapeutic strategy for B cell mediated autoimmune
and
inflammatory disorders such as RA and also a promising strategy for
certain
cancers with malignant B cells.
Trubion and Wyeth also will collaborate on a multi-target
discovery
program focused on the development of certain other
biopharmaceutical products
for major indications with unmet medical needs. Wyeth will receive
worldwide
rights to CD20-targeted SMIPs as will as SMIP product candidates
from the
discovery program.
As part of the transaction, Trubion received an initial $40
million
payment. Trubion will retain an option to co-promote CD20-targeted
therapies
in the United States for certain indications. Wyeth will be
responsible for
future development and commercialization costs for the alliance. The
agreement also provides for additional payments to Trubion upon the
achievement of certain development milestones, royalties on product
sales, and
a stock purchase when Trubion makes a qualified initial public
offering. If
all milestones are achieved the total payments to Trubion could
exceed $800
million, excluding royalties and co-promotion fees.
"Wyeth is excited about the development of TRU-015 for RA as
well as the
potential application of TRU-015 in other chronic inflammatory and B
cell
mediated diseases," says Robert R. Ruffolo, Ph.D., President, Wyeth
Research
and Development and Senior Vice President, Wyeth. "We are proud to
partner
with Trubion because of the high quality of their science in an area
that
matches well with two of Wyeth's key therapeutic areas --
inflammation and
oncology."
"We look forward to working with Wyeth both to maximize the
commercial
potential of TRU-015 and to leverage the productivity of Trubion's
SMIP
technology platform. Trubion chose Wyeth for this collaboration
because of
its leadership in the field of rheumatoid arthritis, bioprocess
development
and its success in the commercialization of biopharmaceuticals,"
says Peter A.
Thompson, MD, FACP, President and Chief Executive Officer, Trubion
Pharmaceuticals. "The strength of Wyeth's science and global
capabilities
makes this collaboration a great fit for Trubion."
Wyeth Pharmaceuticals is the fourth largest fully integrated
biotechnology
pharmaceutical company in the world with capacity to discover,
develop,
manufacture and commercialize biological therapeutics.

About Wyeth
Wyeth is one of the world's largest research-driven
pharmaceutical and
health care products companies. It is a leader in the discovery,
development,
manufacturing and marketing of pharmaceuticals, vaccines,
biotechnology
products and nonprescription medicines that improve the quality of
life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health.
Wyeth Pharmaceuticals has leading products in the areas of
gastroenterology,
women's health care, cardiovascular disease, central nervous system,
inflammation, hemophilia, oncology, and vaccines. For additional
information
visit http://www.wyeth.com.

About Trubion
Trubion Pharmaceuticals is a biopharmaceutical company focused
on the
discovery, development and commercialization of novel medicines to
treat
inflammatory disease and cancer. Trubion was founded in Seattle,
Washington
in 2002 to utilize proprietary technology to develop medicines that
are more
effective and safer than currently available therapies. For
additional
information visit http://www.trubion.com.

The statements in this press release that are not historical
facts are
forward-looking statements based on current expectations of future
events that
involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research,
product
development, manufacturing, and commercialization, and economic
conditions,
including interest and current exchange rate fluctuations, the
impact of
competitive or generic products, product liability and other types of
lawsuits, the impact of legislative and regulatory compliance and
obtaining
approvals, and patents, and other risks and uncertainties, including
those
detailed from time to time in Wyeth's periodic reports, including
quarterly
reports on Form 10-Q and the Annual Report on Form 10-K, filed with
the
Securities and Exchange Commission. Actual results may vary
materially from
the forward-looking statements. The Company assumes no obligation
to publicly
update any forward-looking statements, whether as a result of new
information,
future events or otherwise.

SOURCE Wyeth
Web Site: http://www.wyeth.com http://www.trubion.com

http://www.arizonabiotech.com/
http://www.quotescentral.com/index.php
http://groups.yahoo.com/group/biotech-news/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Biotech flourishes in 2005 while Big Pharma is on the decline | WTN

Biotech flourishes in 2005 while Big Pharma is on the decline | WTN

Biotech flourishes in 2005 while Big Pharma is on the decline
Michael Rosen • Published 01/04/06
Print this article • E-mail this article • Add your opinion
Goodbye, 2005, and hello, 2006! I sit hear writing this article as I listen, appropriately, to a new Cream anthology album called "Cream Gold" (released in 2005 - not to be confused with the live Cream concerts held in 2005). Why Cream, you may ask? Well, the successful re-emergence of this supergroup in 2005 via a series of concerts held in London and NewYork's Madison Square Gardens marked a 2005 musical highlight for any baby-boomer. I caught a part of these concerts on public TV, and was surprised by how good they (Eric Clapton, Ginger Baker, and Jack Bruce) sounded considering they hadn't played together in more than 35 years.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

Sunday, January 01, 2006

CITIZEN-TIMES.com: Biotech research a symbol of chan

CITIZEN-TIMES.com: Biotech research a symbol of changing N.C. economy

Business '06: Biotech research a symbol of changing N.C. economy
by PAUL NOWELL, THE ASSOCIATED PRESS
published January 2, 2006 6:00 am
Reader Feedback: Comment on this article | Register here
AdvertisementKANNAPOLIS, N.C. (AP) — It's hard to envision the huge piles of demolished brick, wood and metal at one end of downtown Kannapolis as a beacon of hope for North Carolina's economy.

Giant yellow cranes are slowly tearing down the 5.8-million-square-foot Pillowtex Plant No. 1 — preparing to remake the site as a planned $1 billion, 350-acre biotechnology research campus.

Once, Kannapolis was at the geographic and figurative heart of Southern textile manufacturing, an industry that helped power the booming growth of an entire region.

Now, California billionaire David Murdock — who owned what was then called Cannon Mills in the 1980s, during its long slide toward the 2003 demise of successor firm Pillowtex — wants to make the "City of Looms" the base camp in a campaign to wrench North Carolina's economy from its agricultural and manufacturing roots into a global, 21st century market of biotech and genetic research.

Murdock's blockbuster unveiling of his plans for a Kannapolis makeover was the state's top business story of 2005, eclipsing the continued record profitability of Charlotte's big banks and the ongoing financial, regulatory and legal mess at Winston-Salem doughnut-maker Krispy Kreme.

Murdock, owner of privately held Dole Food Co., expects the North Carolina Research Campus — now in its first stage of construction — to attract $1 billion of investment, draw in 100 or more biotechnology firms and create as many as 35,000 jobs in a part of the state still suffering from the loss of traditional manufacturing jobs, with their steady pay and good benefits.

Quotes
Love Quotes
Love Quotes
Love Quotes
Life Quotes
Life Quotes

Biotech News 0 comments

Subscribe to biotech-news